How basal are triple‐negative breast cancers?
暂无分享,去创建一个
Daniel Birnbaum | Pascal Finetti | François Bertucci | F. Bertucci | D. Birnbaum | P. Finetti | B. Esterni | N. Cervera | F. Hermitte | P. Viens | Patrice Viens | Fabienne Hermitte | Nathalie Cervera | Benjamin Esterni
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[3] S. Michiels,et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[5] T. Sørlie,et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.
[6] P. Dam,et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.
[7] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[9] Nicolas Stransky,et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. , 2005, Cancer research.
[10] M. Sasa,et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple‐negative breast cancer , 2008, Journal of surgical oncology.
[11] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Amy V Kapp,et al. Discovery and validation of breast cancer subtypes , 2006, BMC Genomics.
[14] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[16] C. Perou,et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.
[17] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[18] Puay Hoon Tan,et al. Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.
[19] Daniel Birnbaum,et al. Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.
[20] Marc Tischkowitz,et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.
[21] Daniel Birnbaum,et al. Basal and luminal breast cancers: basic or luminous? (review). , 2004, International journal of oncology.
[22] Daniel Birnbaum,et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.
[23] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[24] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[26] Harry Bartelink,et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.
[27] Daniel Birnbaum,et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.
[28] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[29] Wolfgang Heller,et al. Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.
[30] T. Nielsen,et al. Deconstructing the molecular portrait of basal-like breast cancer. , 2006, Trends in molecular medicine.
[31] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.